Human Papillomavirus Vaccine Impact Monitoring Project Across CT (HPV-IMPACT)
This project aims to monitor the impact of human papillomavirus (HPV) vaccine on cervical cancer precursors and HPV types associated with those precursors.
Goals & Objectives
- Monitor HPV vaccine impact on cervical cancer precursors, cervical intraepithelial neoplasia (CIN) grade 2 and 3 and adenocarcinoma in situ (AIS).
- Monitor HPV vaccine impact on HPV types associated with CIN 2/3 and AIS lesions.
- Improve public health practice through local population-based surveillance of HPV-related cervical cancer precursors.
Statewide passive monitoring of CIN2/3 and AIS diagnoses from pathology laboratories
Population-based active surveillance for CIN 2/3 and AIS in New Haven county
enhanced data collection to determine HPV vaccination status specimen collection to determine HPV type associated with CIN2/3 and AIS diagnoses.
1. Linda M. Niccolai, Niti R. Mehta, James L. Hadler. Racial/Ethnic and poverty disparities in human papillomavirus vaccination completion. American Journal of Preventive Medicine. 2011;41(4):428-33.
2. DPH. Human Papillomavirus Types in Connecticut 2008-2009. Connecticut Epidemiologist 2011;31(6):25-26.
3. DPH. The Human Papillomavirus Vaccine Impact Monitoring Project (HPV-IMPACT) - Connecticut, 2008. Connecticut Epidemiologist 2010;30(2):5-6.
4. Susan Hariri, Elizabeth R. Unger, Suzanne E. Powell, Heidi M. Bauer, Nancy M. Bennett, Karen C. Bloch , Linda M. Niccolai, Sean Schafer, Lauri E. Markowitz, The HPV-IMPACT Working Group. The HPV vaccine impact monitoring project (HPV-IMPACT): assessing early evidence of vaccination impact on HPV-associated cervical cancer precursor lesions. Cancer Causes Control. 2011 Nov 23. [Epub ahead of print]
Article about the CT HPV-IMPACT project in the Fall 2011 issue of Yale Public Health: Tracking HPV.
Project Contact Person
Pam Julian, MPH
Connecticut Emerging Infections Program
One Church Street, 7th floor
New Haven, CT 06510